Cargando…

Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma

Some patients with basal cell carcinoma develop a large number of basal cell carcinomas during their lives. The most common underlying genetic disease that causes multiple basal cell carcinomas is basal cell naevus syndrome. Basal cell naevus syndrome is caused by a germline mutation in patched-1 (P...

Descripción completa

Detalles Bibliográficos
Autores principales: VERKOUTEREN, Babette J. A., SINX, Kelly A. E., REINDERS, Marie G. H. C., AARTS, Maureen J. B., MOSTERD, Klara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631257/
https://www.ncbi.nlm.nih.gov/pubmed/35535645
http://dx.doi.org/10.2340/actadv.v102.980
_version_ 1784823778573811712
author VERKOUTEREN, Babette J. A.
SINX, Kelly A. E.
REINDERS, Marie G. H. C.
AARTS, Maureen J. B.
MOSTERD, Klara
author_facet VERKOUTEREN, Babette J. A.
SINX, Kelly A. E.
REINDERS, Marie G. H. C.
AARTS, Maureen J. B.
MOSTERD, Klara
author_sort VERKOUTEREN, Babette J. A.
collection PubMed
description Some patients with basal cell carcinoma develop a large number of basal cell carcinomas during their lives. The most common underlying genetic disease that causes multiple basal cell carcinomas is basal cell naevus syndrome. Basal cell naevus syndrome is caused by a germline mutation in patched-1 (PTCH1), a tumour suppressor gene of the hedgehog signalling pathway. However, in a significant portion of patients with multiple basal cell carcinomas, no underlying genetic cause is found. Nevertheless, these patients can experience a treatment burden comparable to that of patients with basal cell naevus syndrome. They are referred to as high-frequency basal cell carcinoma patients. Hedgehog pathway inhibitors were the first group of targeted therapy for basal cell carcinomas. This study reviews the literature on hedgehog pathway inhibitor therapy for patients with basal cell naevus syndrome or high-frequency basal cell carcinoma, to provide an overview on efficacy, safety, dosing regimens, tumour resistance and reoccurrence, and health-related quality of life.
format Online
Article
Text
id pubmed-9631257
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Society for Publication of Acta Dermato-Venereologica
record_format MEDLINE/PubMed
spelling pubmed-96312572022-11-17 Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma VERKOUTEREN, Babette J. A. SINX, Kelly A. E. REINDERS, Marie G. H. C. AARTS, Maureen J. B. MOSTERD, Klara Acta Derm Venereol Review Article Some patients with basal cell carcinoma develop a large number of basal cell carcinomas during their lives. The most common underlying genetic disease that causes multiple basal cell carcinomas is basal cell naevus syndrome. Basal cell naevus syndrome is caused by a germline mutation in patched-1 (PTCH1), a tumour suppressor gene of the hedgehog signalling pathway. However, in a significant portion of patients with multiple basal cell carcinomas, no underlying genetic cause is found. Nevertheless, these patients can experience a treatment burden comparable to that of patients with basal cell naevus syndrome. They are referred to as high-frequency basal cell carcinoma patients. Hedgehog pathway inhibitors were the first group of targeted therapy for basal cell carcinomas. This study reviews the literature on hedgehog pathway inhibitor therapy for patients with basal cell naevus syndrome or high-frequency basal cell carcinoma, to provide an overview on efficacy, safety, dosing regimens, tumour resistance and reoccurrence, and health-related quality of life. Society for Publication of Acta Dermato-Venereologica 2022-06-12 /pmc/articles/PMC9631257/ /pubmed/35535645 http://dx.doi.org/10.2340/actadv.v102.980 Text en © 2022 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license
spellingShingle Review Article
VERKOUTEREN, Babette J. A.
SINX, Kelly A. E.
REINDERS, Marie G. H. C.
AARTS, Maureen J. B.
MOSTERD, Klara
Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma
title Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma
title_full Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma
title_fullStr Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma
title_full_unstemmed Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma
title_short Update on Hedgehog Pathway Inhibitor Therapy for Patients with Basal Cell Naevus Syndrome or High-frequency Basal Cell Carcinoma
title_sort update on hedgehog pathway inhibitor therapy for patients with basal cell naevus syndrome or high-frequency basal cell carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631257/
https://www.ncbi.nlm.nih.gov/pubmed/35535645
http://dx.doi.org/10.2340/actadv.v102.980
work_keys_str_mv AT verkouterenbabetteja updateonhedgehogpathwayinhibitortherapyforpatientswithbasalcellnaevussyndromeorhighfrequencybasalcellcarcinoma
AT sinxkellyae updateonhedgehogpathwayinhibitortherapyforpatientswithbasalcellnaevussyndromeorhighfrequencybasalcellcarcinoma
AT reindersmarieghc updateonhedgehogpathwayinhibitortherapyforpatientswithbasalcellnaevussyndromeorhighfrequencybasalcellcarcinoma
AT aartsmaureenjb updateonhedgehogpathwayinhibitortherapyforpatientswithbasalcellnaevussyndromeorhighfrequencybasalcellcarcinoma
AT mosterdklara updateonhedgehogpathwayinhibitortherapyforpatientswithbasalcellnaevussyndromeorhighfrequencybasalcellcarcinoma